1e
19
1
49
2
2
18
1b
1d
18
33
8c
1d
2 29
1d
25
Shannon R McCurdy, MD
78
8c
Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
7
5f
Department: Medicine
4
1
b
1d
46
Contact information
54
4
3
3
1d
54
Perelman Center for Advanced Medicine
1e 3400 Civic Center Blvd
34 12 South Pavilion
Philadelphia, PA 19104
26
1e 3400 Civic Center Blvd
34 12 South Pavilion
Philadelphia, PA 19104
2d
Office: 12156140698
30 Fax: 2156155890
24
f
30 Fax: 2156155890
24
18
Publications
23 a
3
2
29
4
b
1f
23 a
13
Education:
21 7 BA 25 (English and Pre-Medical ) c
2a Emory University , 2005.
21 7 MD 15 (Medicine) c
41 Georgetown University School of Medicine, 2009.
c
3
3
3
3
8d
Permanent link21 7 BA 25 (English and Pre-Medical ) c
2a Emory University , 2005.
21 7 MD 15 (Medicine) c
41 Georgetown University School of Medicine, 2009.
c
2 29
21
1e
1d
24
5e
71
e 29
27
Description of Clinical Expertise
545 While HLA-matched related sibling donors are available for ~30%, they are more difficult to identify for older patients given that their siblings will also be older and often have medical comorbidities that exclude them from donating. In addition, older donor age may be associated with a greater risk of graft failure. As such, I have worked to expand the availability of allogeneic transplantation to older patients through HLA-haploidentical transplantation with post-transplant cyclophosphamide, which allows us to use children, grandchildren, nieces, and nephews as donors. Another former barrier to transplanting older patients was the intensity of conditioning. Historically allogeneic transplantation was limited to patients younger than 50 due to high treatment-related mortality associated with myeloablation. In my work, I demonstrated that utilizing nonmyeloablative HLA-haploidentical transplantation for patients in their 70’s and 60’s yielded similar outcomes to patients undergoing transplantation in their 50’s. In addition to an expertise in allogeneic transplantation, I specialize in the treatment of all phases of care for patients with acute lymphoblastic leukemia and myeloid diseases including acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative neoplasms, and chronic myeloid leukemia.71
Description of Research Expertise
997 Allogeneic blood or marrow transplantation is the only potentially curative option for patients with relapsed, refractory, or high-risk hematologic malignancies. Unfortunately, only a third of patients have an available HLA-matched related donor. Partially HLA-mismatched related (HLA-haploidentical) transplantation allows identification of a donor for the vast majority of patients. In the past, HLA-haploidentical transplantation was associated with excessive nonrelapse mortality and poor overall survival. My research has contributed to the understanding of a novel technique that utilizes post-transplant cyclophosphamide as graft-versus-host disease prophylaxis after HLA-haploidentical transplantation. Using risk stratification with the disease risk index developed by Armand et al., I demonstrated that outcomes after nonmyeloablative HLA-haploidentical transplantation are comparable to that after reduced intensity HLA-matched transplantation. Similar to my work in older patients described above, I have also shown that nonmyeloablative HLA-haploidentical transplantation is safe and effective for pediatric and young adult patients. In addition, I have contributed to research examining early biomarkers, such as ST2, as predictors of nonrelapse mortality after HLA-haploidentical transplantation. Finally, to improve outcomes further, I have conducted research to examine the association of donor characteristics with transplantation outcomes. I showed that parent donors were associated with more graft failure when compared with sibling or offspring donors, but that survival was no different. Importantly, in that analysis, survival was affected by recipient age with recipients over 55 having inferior survival to younger patients. This work supports my proposed research agenda to evaluate the utility of the frailty phenotype tools to predict an older patient’s risk of nonrelapse mortality after induction chemotherapy and allogeneic transplantation as discussed in this proposal. Finally, my research has contributed to the widespread adoption of HLA-haploidentical transplantation with post-transplant cyclophosphamide, I have advanced the understanding of how we can improve its outcomes further, and I hope to continue to advance the field through studying frailty phenotype assessments in older patients with leukemia and myeloid malignancies undergoing induction then consolidative allogeneic transplantation.e 29
23
1d7 Jimenez Jimenez AM, Spellman SR, Politikos I, McCurdy SR, Devine SM, Malki MMA, Bolon YT, Lee SJ, Dehn J, Pidala J, Maiers M, Askar M, Malmberg C, Auletta JJ, Stefanski H, Broglie L, Qayed M, Horwitz M, Wilder JS, Gooptu M, Mehta RS, Fernandez-Viña M, Shaw BE, Shaffer BC.: Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR. Transplant Cell Ther Jul 2025.
228 Sorror ML, Saber W, Logan B, Geller N, Bellach A, Kou J, Wood W, McCarty JM, Knight TG, Runaas L, Johnston L, Walston J, Nakamura R, Jarrett L, Mishra A, Uberti J, Dahi PB, Saultz JN, McCurdy SR, Morris LE, Imus PH, Hogan WJ, Nadiminti K, Bhatt VR, Olin R, Maakaron J, Sobecks R, Wall SA, Mattila D, Protz B, Devine SM, Horowitz MM, Artz AS.: Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704. Blood Adv 9: 3268-3280, Jul 2025.
1af Mehta RS, Choe H, Saultz J, Gong Z, Sharma P, Al-Juhaishi T, Petitto GS, Lazaryan A, Singh A, Xue E, Dimitrova D, Hyder M, McCurdy S, Im A, Huber B, Aljawai YM, Kanakry J, Milano F, Kanakry CG.: Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation. Am J Hematol Jun 2025.
2cb Munshi PN, Olin RL, Wall S, McCurdy SR, Al-Juhaishi T, Baker J, Bhatt VR, Chokr N, Dahi P, DeFilipp Z, Espinoza-Gutarra M, Farhan S, Gowda L, Hamilton BK, Inamoto Y, Jayani R, Kharfan-Dabaja MA, Lin R, Meyers G, Mishra A, Murthy HS, Nawas M, Rosko AE, Ruiz M, Sorror ML, Sung AD, Carpenter PA, Hamadani M, Artz AS.: US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines. Transplant Cell Ther May 2025.
1a2 Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S, Hexner E, Hirsh R, Hossain N, Lai C, Loren A, Luger S, Maillard I, McCurdy S, Matthews A, Martin ME, Paralkar VR, Perl A, Porter D, Pratz K, Stadtmauer E, Bruno XJ.: Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen. Eur J Haematol Apr 2025.
24d Greenberg PL, Stone RM, Abaza Y, Al-Kali A, Anand S, Ball B, Bennett JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, DeZern AE, Gaensler K, Gahvari Z, Garcia-Manero G, Griffiths EA, Haque T, Jacoby M, Jonas BA, Keel S, Khanal R, Kishtagari A, Madanat Y, Maness LJ, McCurdy SR, McMahon C, Odenike O, Osman A, Reddy VV, Sallman DA, Sayar H, Shallis R, Singh A, Tanaka T, Thota S, Kovach E, Nguyen J, Hochstetler C.: NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025. J Natl Compr Canc Netw Mar 2025.
2be Alison Carulli, Brendan L. Mangan, Rachel Hartman, Mrs. Lindsey MacDonald, Christopher J. Catania, Noelle V. Frey, Saar Gill, Elizabeth O Hexner, Mary Ellen Martin, Nasheed M. Hossain, Alison W. Loren, Selina M. Luger, MD6, Shannon R. McCurdy, David L Porter, Keith W. Pratz,Jacqueline Smith, and Pashna Munshi.: Early Mixed Chimerism and Relapse Rates for Acute Myeloid Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Tandem Meetings of the American Society of Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant, Honolulu, HI. Feb 2025.
356 Shannon R. McCurdy, Anthony D Sung, Rebecca T. Brown, Marni Kessler, Nelson J. Chao, Thuy T. Koll, Alfred Fisher,Ernaya Johnson, Meagan Lew, Lauren Bohannon, Sanghee Hong, Pashna Munshi, Saar I. Gill, Nasheed M. Hossain, Sarah Skuli, Noelle V. Frey, Elizabeth O Hexner, Ximena Jordan Bruno, Daria Babushock, Catherine E. Lai, Mary Ellen Martin, Selina M. Luger, David L Porter, Alison W. Loren, Vijaya Raj Bhatt, and Phyllis Gimotty.: Machine Learning Models Demonstrate Gait Speed As the Best Predictor of Survival and Relapse-Free Survival in Older Adults Undergoing Allogeneic Hematopoietic Cell Transplantation. Tandem Meetings of the American Society of Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant, Honolulu, HI. Feb 2025.
319 Ashley D. Hadjis, Honghong Sun, Yangzhu Du, Rebecca T. Brown, Pashna Munshi,Saar I. Gill, Nasheed M. Hossain, Sarah Skuli, Noelle V. Frey, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine E. Lai, Mary Ellen Martin, Selina M. Luger, David L Porter, Alison W. Loren, and Shannon R. McCurdy.: Graft-Versus-Host Disease (GVHD) and Senescence-Associated Biomarkers Correlate with Frailty and Survival in Older Adults Undergoing Hematopoietic Cell Transplantation (HCT). Tandem Meetings of the American Society of Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research, Oral Abstract - Session G - Late Effects and Aging, Honolulu, HI. Feb 2025 Notes: "Oral Presentation"
2c
7
1d
1f
Selected Publications
291 Shannon R. McCurdy, Scott R. Solomon, Brian C. Shaffer, Meilun He, Yung-Tsi Bolon, Amanda G. Blouin, Alla Keyzner, Francisco A. Socola, Uroosa Ibrahim, Jun Zou, Hana Safah, Nakhle Saba, Shahinaz Gadalla, Miguel-Angel Perales, Sophie Paczesny, Steven G.E. Marsh, Effie W. Petersdorf, Tao Wang, Stephanie J. Lee, Ephraim J. Fuchs: Post-Transplant Cyclophosphamide Improves Survival in HLA-DPB1 Mismatched Unrelated Donor Allogeneic Transplantation. Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy October 2025.1d7 Jimenez Jimenez AM, Spellman SR, Politikos I, McCurdy SR, Devine SM, Malki MMA, Bolon YT, Lee SJ, Dehn J, Pidala J, Maiers M, Askar M, Malmberg C, Auletta JJ, Stefanski H, Broglie L, Qayed M, Horwitz M, Wilder JS, Gooptu M, Mehta RS, Fernandez-Viña M, Shaw BE, Shaffer BC.: Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR. Transplant Cell Ther Jul 2025.
228 Sorror ML, Saber W, Logan B, Geller N, Bellach A, Kou J, Wood W, McCarty JM, Knight TG, Runaas L, Johnston L, Walston J, Nakamura R, Jarrett L, Mishra A, Uberti J, Dahi PB, Saultz JN, McCurdy SR, Morris LE, Imus PH, Hogan WJ, Nadiminti K, Bhatt VR, Olin R, Maakaron J, Sobecks R, Wall SA, Mattila D, Protz B, Devine SM, Horowitz MM, Artz AS.: Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704. Blood Adv 9: 3268-3280, Jul 2025.
1af Mehta RS, Choe H, Saultz J, Gong Z, Sharma P, Al-Juhaishi T, Petitto GS, Lazaryan A, Singh A, Xue E, Dimitrova D, Hyder M, McCurdy S, Im A, Huber B, Aljawai YM, Kanakry J, Milano F, Kanakry CG.: Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation. Am J Hematol Jun 2025.
2cb Munshi PN, Olin RL, Wall S, McCurdy SR, Al-Juhaishi T, Baker J, Bhatt VR, Chokr N, Dahi P, DeFilipp Z, Espinoza-Gutarra M, Farhan S, Gowda L, Hamilton BK, Inamoto Y, Jayani R, Kharfan-Dabaja MA, Lin R, Meyers G, Mishra A, Murthy HS, Nawas M, Rosko AE, Ruiz M, Sorror ML, Sung AD, Carpenter PA, Hamadani M, Artz AS.: US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines. Transplant Cell Ther May 2025.
1a2 Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S, Hexner E, Hirsh R, Hossain N, Lai C, Loren A, Luger S, Maillard I, McCurdy S, Matthews A, Martin ME, Paralkar VR, Perl A, Porter D, Pratz K, Stadtmauer E, Bruno XJ.: Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen. Eur J Haematol Apr 2025.
24d Greenberg PL, Stone RM, Abaza Y, Al-Kali A, Anand S, Ball B, Bennett JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, DeZern AE, Gaensler K, Gahvari Z, Garcia-Manero G, Griffiths EA, Haque T, Jacoby M, Jonas BA, Keel S, Khanal R, Kishtagari A, Madanat Y, Maness LJ, McCurdy SR, McMahon C, Odenike O, Osman A, Reddy VV, Sallman DA, Sayar H, Shallis R, Singh A, Tanaka T, Thota S, Kovach E, Nguyen J, Hochstetler C.: NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025. J Natl Compr Canc Netw Mar 2025.
2be Alison Carulli, Brendan L. Mangan, Rachel Hartman, Mrs. Lindsey MacDonald, Christopher J. Catania, Noelle V. Frey, Saar Gill, Elizabeth O Hexner, Mary Ellen Martin, Nasheed M. Hossain, Alison W. Loren, Selina M. Luger, MD6, Shannon R. McCurdy, David L Porter, Keith W. Pratz,Jacqueline Smith, and Pashna Munshi.: Early Mixed Chimerism and Relapse Rates for Acute Myeloid Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Tandem Meetings of the American Society of Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant, Honolulu, HI. Feb 2025.
356 Shannon R. McCurdy, Anthony D Sung, Rebecca T. Brown, Marni Kessler, Nelson J. Chao, Thuy T. Koll, Alfred Fisher,Ernaya Johnson, Meagan Lew, Lauren Bohannon, Sanghee Hong, Pashna Munshi, Saar I. Gill, Nasheed M. Hossain, Sarah Skuli, Noelle V. Frey, Elizabeth O Hexner, Ximena Jordan Bruno, Daria Babushock, Catherine E. Lai, Mary Ellen Martin, Selina M. Luger, David L Porter, Alison W. Loren, Vijaya Raj Bhatt, and Phyllis Gimotty.: Machine Learning Models Demonstrate Gait Speed As the Best Predictor of Survival and Relapse-Free Survival in Older Adults Undergoing Allogeneic Hematopoietic Cell Transplantation. Tandem Meetings of the American Society of Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant, Honolulu, HI. Feb 2025.
319 Ashley D. Hadjis, Honghong Sun, Yangzhu Du, Rebecca T. Brown, Pashna Munshi,Saar I. Gill, Nasheed M. Hossain, Sarah Skuli, Noelle V. Frey, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine E. Lai, Mary Ellen Martin, Selina M. Luger, David L Porter, Alison W. Loren, and Shannon R. McCurdy.: Graft-Versus-Host Disease (GVHD) and Senescence-Associated Biomarkers Correlate with Frailty and Survival in Older Adults Undergoing Hematopoietic Cell Transplantation (HCT). Tandem Meetings of the American Society of Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research, Oral Abstract - Session G - Late Effects and Aging, Honolulu, HI. Feb 2025 Notes: "Oral Presentation"
2c